Poster Presentation Joint 2016 COSA and ANZBCTG Annual Scientific Meeting

Use of Positron Emission Tomography (PET) scan in breast cancer – a single centre study (#266)

Veenoo AGARWAL 1 , Hillary Martin 1
  1. Fiona Stanley Hospital, Murdoch, WA, Australia

Background: The role of positron emission tomography (PET scan) is in breast cancer is not yet clearly defined. PET scan has been shown to have potential for utility for management of breast cancer patients in a variety of settings, particularly with reference to metastatic disease. The aim of this project is to summarise current clinical practice at a single centre regarding the use of PET-CT for breast cancer and assess its utility in patient management. Method: All PETs performed at FSH were screened to identify those requested for patients known to have breast cancer. Details of the request indication, requesting clinician, and other investigations ordered prior or following the imaging request were also recorded. The PET reports were also screened for any new findings that directly led to change of management. Results: A total of 16 scans were done during the study period, 8 were ordered by Medical Oncologist, 5 by general practitioners, and 3 by other clinicians. Three were performed for patients with localised disease to investigate for potential metastatic disease, and 12 for patients with known metastatic disease. 8 scans resulted in findings which altered patient management subsequently. These findings included a suspicious ovarian lesion, subsequently diagnosed to be ovarian cancer, and progression of disease not seen on other modalities of imaging. Of the 8 scans that showed new findings, which altered management, 5 were generated by Oncologist. Conclusion: PET is being used, but infrequently for patients with breast cancer. For 50% of the patients, the PET scan results altered subsequent patient management. This imaging modality should be considered in selected cases, with further prospective research required.